Page 24 - ஓக்லஹோமா மருத்துவ ஆராய்ச்சி அடித்தளம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Fluidigm s FDA-EUA Authorized Saliva-based SARS-CoV-2 RT-PCR Assay - Now for use in India ANI | Updated: Dec 24, 2020 17:27 IST New Delhi [India], December 24 (ANI/NewsVoir): It s been a year now since the first few human cases of COVID-19 infection were reported amidst the busy wholesale food market of China s Wuhan city. The disease caused by SARS-CoV-2 virus, thought to have its origin in Bats, soon spread to cause worldwide outbreaks & escalated to a global pandemic. The latest statistics indicate 46.5 Million cases reported to date worldwide with the global mortality rate around 2.5% and India ranking second at 8.23M cases till date. COVID-19 has brought with it the need for SARS-CoV-2 tracking, surveillance & diagnosis. Countries that adopted testing strategies early on were able to test, track & isolate individuals that showed disease symptoms & hence were better able to contain the disease spread. While antibody testing was initially

United statesNew delhiPremas lifesciencesPraveen guptaChris linthwaiteOklahoma medical research foundationPremas lifesciences pvt ltdFluidigm biomarkMedical research foundationEmergency use authorizationSars cov 2 rt pcrCorona virusஒன்றுபட்டது மாநிலங்களில்புதியது டெல்ஹிப்ரவீன் குப்தாஓக்லஹோமா மருத்துவ ஆராய்ச்சி அடித்தளம்